Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
NEW YORK and WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced it was selected by Great Place To Work® and Fortune magazine for the 2026 Fortune Best Workplaces in BioPharma™ List. This is Dianthus’ inaugural appearance on the list, ranking among the top 30 small- and medium-sized biotechnology and pharmaceutical companies in the United States. The Company was recognized for fostering a high-trust and engaging workplace culture.
Covered in this story
What has happened since
- Dianthus Therapeutics Inc is up 1.2% since this was published, 9 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $DNTH yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Dianthus Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.